-- 브렌탁과의 오랜 파트너십 보완하는 아젤리스와의 새로운 협력 관계로 SI 그룹의 고객 접근성 확대 기대 더 우드랜즈, 텍사스, 2025년 10월 4일 -- 세계적인 고성능 첨가제, 생산 공정 솔루션, 의약품, 유기화학물 중간체 개발사이자 제조사인 SI 그룹(SI Group)이 2일 유럽·중동·아프리카(EMEA) 지역에서 플라스틱 첨가제 유통망을 확장하기 위해 아젤리스(Azelis)와 새로운 파트너십을 체결했다고 밝혔다. 2026년 1월 1일부터 시작되는 이번 파트너십을 통해 SI 그룹은 영향력을 확대하고 맞춤형 솔루션 및 현지 지원을 통해 고객 서비스 역량을 강화할 예정이다. SI 그룹은 또 신뢰할 수 있는 유통 파트너인 브렌탁(Brenntag)과 2005년부터 이어온 협력을 EMEA 지역 일부 국가에서 계속 이어갈 계획이다. SI 그룹은 아젤리스와 브렌탁이 시장에서 가장 큰 영향력을 발휘할 수 있는 지역에 집중하기 위한 전략적 차원에서 양사와의 파트너십을 결정했다. SI 그룹은 양사의 영업 인력 역량, 기술 전문성, 창고 관리 능력을 활용해 고객의 제품 접근성과 고객 지원 서비스를 강화하
DA NANG, Vietnam, Oct. 3, 2025 -- Da Nang is set to host the Da Nang Global Business Summit 2025 under the theme "Unlocking the Future of Medical & Wellness Tourism: Innovation – Creativity – Global Connectivity". The two-day event will take place on November 11–12, 2025, at Fusion Resort & Villas Da Nang, affirming the city's ambition to become a leading hub for medical tourism in the region. The summit is expected to welcome over 200 senior leaders and policymakers from international hospitals, technology corporations, tourism enterprises, and government age
Over 200 representatives from hospitals and medical institutions, together with doctors, gathered to celebrate their shared achievements HONG KONG, Oct. 3, 2025 -- Prudential Hong Kong Limited ("Prudential") hosted the Health Partnership Networking Cocktail Reception yesterday at the JW Marriott Hotel Hong Kong. The event welcomed over 200 distinguished guests, including HKSAR Executive Council Member Dr. Ko Wing-man, alongside doctors and representatives from hospitals and medical institutions across Chinese mainland, Hong Kong, and Macau. The reception served as a d
HEIDELBERG, Germany, Oct. 3, 2025 -- Mediso completes the installation of an AnyScan® TRIO-TheraMAX SPECT/CT at the Department of Nuclear Medicine at Heidelberg University Hospital. The system is specifically designed for the clinical needs of theranostic imaging. Its detectors and collimators are developed for Targeted Radionuclide Therapies carried out with radioisotopes emitting alpha and beta particles and have co-emission of high and ultra-high energy gamma photons that are more challenging to image than diagnostic 99mTc. This requires maximized performance for
HEIDELBERG, Germany, Oct. 3, 2025 -- Mediso completes the installation of an AnyScan® TRIO-TheraMAX SPECT/CT at the Department of Nuclear Medicine at Heidelberg University Hospital. The system is specifically designed for the clinical needs of theranostic imaging. Its detectors and collimators are developed for Targeted Radionuclide Therapies carried out with radioisotopes emitting alpha and beta particles and have co-emission of high and ultra-high energy gamma photons that are more challenging to image than diagnostic 99mTc. This requires maximized performance for
SINGAPORE, Oct. 3, 2025 -- Singapore General Hospital (SGH) has announced the launch of a Centre of Excellence (CoE) for robotic-assisted surgery, ensuring orthopaedic surgeons are equipped with knowledge of emerging technologies as the population ages and surgical needs evolve. The Centre is established as part of a two-year strategic collaboration, formalised through a Memorandum of Understanding (MoU), with Johnson & Johnson MedTech with an initial focus on training and research in total knee replacement. Regional Training Hub for Southeast Asia The
MELBOURNE, Australia, Oct. 3, 2025 -- Diagnostics company Nutromics has presented the world's first real-time, continuous data on two critical antibiotics - vancomycin and tobramycin - measured simultaneously on the same device in animal models. The breakthrough was unveiled at the International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) in Singapore. The study, conducted in rats, demonstrated the Nutromics platform's ability to continuously track levels of multiple targets on the one device ('multiplexing'). Both vancomycin, among the most frequently dos
TEL AVIV, Israel, Oct. 3, 2025 -- MedHub-AI today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved national reimbursement for the company's AutocathFFR™ System, effective October 1, 2025. The decision follows regulatory approval by the Pharmaceuticals and Medical Devices Agency (PMDA) earlier this year and marks a significant milestone in expanding access to advanced coronary physiology assessment in Japan. The approval provides physicians and hospitals across Japan with broad access to AutocathFFR, the first fully automated, real-time AI-b
HONG KONG, Oct. 2, 2025 -- A landmark study conducted by The Hong Kong University of Science and Technology (HKUST) has demonstrated that a genetic variant, TREM2 H157Y, significantly increases the risk of Alzheimer's disease (AD) in individuals of ethnic Chinese descent. The research reveals that this variant confers a risk level comparable to that of the strongest known genetic risk factor for AD, APOE-ε4, and is associated with more rapid clinical progression and more severe neurodegeneration. This is the first in the field to conduct an in-depth family-based clinical case study on
New collaboration will expand SI Group's customer reach complementing its long-standing partnership with Brenntag THE WOODLANDS, Texas, Oct. 2, 2025 -- SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals, and chemical intermediates, announced today a new partnership with Azelis to expand its EMEA distribution network for plastics additives. Effective January 1, 2026, the partnership will extend SI Group's reach and strengthen its ability to serve customers with tailored solutions and local support. SI Group will als